Jerel Davis is a PhD-trained life scientist turned venture investor at Versant Ventures who specializes in creating biotech companies from scratch through complex partnerships with big pharma, including co-founding BlueRock Therapeutics with Bayer in a $225M Series A deal. Based in Vancouver, he has been a key architect of Versant's company-creation strategy in Canada, helping launch and scale multiple biotechs like Chinook Therapeutics and Repare Therapeutics while designing many of these ventures from day one with specific strategic acquirers in mind. Jerel Davis is a PhD-trained life scientist turned venture investor at Versant Ventures who specializes in creating biotech companies from scratch through complex partnerships with big pharma, including co-founding BlueRock Therapeutics with Bayer in a $225M Series A deal. Based in Vancouver, he has been a key architect of Versant's company-creation strategy in Canada, helping launch and scale multiple biotechs like Chinook Therapeutics and Repare Therapeutics while designing many of these ventures from day one with specific strategic acquirers in mind.